72 related articles for article (PubMed ID: 27839981)
1. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
2. Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease.
Becker-Cohen M; Revel-Vilk S; Frydman D; Dinur T; Tiomkin M; Istaiti M; Arbel N; Bauer P; Cozma C; Rolfs A; Szer J; Zimran A
Intern Med J; 2024 Mar; 54(3):398-403. PubMed ID: 37493453
[TBL] [Abstract][Full Text] [Related]
3. Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy.
Kilic A; Emecen Sanli M; Ozsaydı Aktasoglu E; Gokalp S; Biberoğlu G; Inci A; Okur I; Suheyl Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2024 May; 37(5):413-418. PubMed ID: 38624096
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.
Deegan P; Lau H; Elstein D; Fernandez-Sasso D; Giraldo P; Hughes D; Zimran A; Istaiti M; Gadir N; Botha J; Revel-Vilk S;
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792324
[No Abstract] [Full Text] [Related]
5. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
Deegan PB; Cox TM
Drug Des Devel Ther; 2012; 6():81-106. PubMed ID: 22563238
[TBL] [Abstract][Full Text] [Related]
6. Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP).
Schiffmann R; Mengel E; Wallace M; Rochmann C; Turnbull J; Krupnick R; Gwaltney C; Pulikottil-Jacob R; Batsu I; Zheng R; Hamed A
Adv Ther; 2024 Jul; 41(7):2907-2923. PubMed ID: 38802634
[TBL] [Abstract][Full Text] [Related]
7. A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.
Bengherbia M; Berger M; Hivert B; Rigaudier F; Bracoud L; Vaeterlein O; Yousfi K; Maric M; Malcles M; Belmatoug N
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792468
[No Abstract] [Full Text] [Related]
8. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Lorber J; Niederau C; Carwile JL; Oliveira-Dos-Santos A; Perichon MG; Uslu Cil S; Kishnani PS
Am J Hematol; 2024 Apr; ():. PubMed ID: 38686876
[TBL] [Abstract][Full Text] [Related]
9. Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.
Elstein D; Belmatoug N; Bembi B; Deegan P; Fernandez-Sasso D; Giraldo P; Göker-Alpan Ö; Hughes D; Lau H; Lukina E; Revel-Vilk S; Schwartz IVD; Istaiti M; Botha J; Gadir N; Schenk J; Zimran A;
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930117
[No Abstract] [Full Text] [Related]
10. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
11. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
12. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey.
Lau H; Belmatoug N; Deegan P; Goker-Alpan O; Schwartz IVD; Shankar SP; Panahloo Z; Zimran A
Blood Cells Mol Dis; 2018 Feb; 68():226-231. PubMed ID: 27839985
[TBL] [Abstract][Full Text] [Related]
13. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J; Belmatoug N; Camou F; Serratrice C; Froissart R; Caillaud C; Levade T; Astudillo L; Serratrice J; Brassier A; Rose C; Billette de Villemeur T; Berger MG
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218669
[TBL] [Abstract][Full Text] [Related]
14. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
Gupta P; Pastores GM
Pediatric Health Med Ther; 2017; 8():73-81. PubMed ID: 29388611
[TBL] [Abstract][Full Text] [Related]
16. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.
Lefebvre T; Reihani N; Daher R; de Villemeur TB; Belmatoug N; Rose C; Colin-Aronovicz Y; Puy H; Le Van Kim C; Franco M; Karim Z
Haematologica; 2018 Apr; 103(4):587-596. PubMed ID: 29305416
[TBL] [Abstract][Full Text] [Related]
17. Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).
Zimran A; Belmatoug N; Bembi B; Deegan P; Elstein D; Fernandez-Sasso D; Giraldo P; Goker-Alpan O; Lau H; Lukina E; Panahloo Z; Schwartz IVD;
Am J Hematol; 2018 Feb; 93(2):205-212. PubMed ID: 29090476
[TBL] [Abstract][Full Text] [Related]
18. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
Zimran A; Goldblatt J; Szer J
Blood Cells Mol Dis; 2018 Feb; 68():14-16. PubMed ID: 28935503
[No Abstract] [Full Text] [Related]
19. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
